Back to Rankings

VVOS

Vivos TherapeuticsB
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
View Chart
Current thesis
The new evidence is incrementally constructive on demand because the May 15, 2026 NT 10-Q points to roughly 70% revenue growth and 100% gross-profit growth for Q1 2026, consistent with management's earlier claim that the SCN-centered model could improve revenue mix and margins [#NT10Q-2026-05-15] [#PR-2026-04-15].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Given the tiny market cap, further equity financing or other capital actions could be materially dilutive even if they help listing compliance.
Momentum
93
Value
36
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.72 · Bull $1.15 · Bear $0.30
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $4.00
Why
Momentum93 · Δ7d -
Value36 · Δ7d -0.0
Sentiment48 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
93
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
36
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
48
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 93.1 / Value 36.3 / Sentiment 48.3

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$9.42M
Beta
6.89
Shares Out
8.99M
P/E (TTM) · Derived
-0.5
P/S (TTM)
1.28
P/FCF (TTM) · Derived
-0.61
Rev YoY
+75.7%
EPS YoY
-24.6%
Gross Margin
+55.7%
Op Margin
-94.3%
Net Debt
-$6.26M
Current Ratio
0.78
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology